Literature DB >> 8131480

AIDS and malignant mesothelioma--is there a connection?

C A Behling1, P L Wolf, P Haghighi.   

Abstract

A 35-year-old male homosexual, a former intravenous drug abuser, was found to be human immunodeficiency virus (HIV) positive in 1984. He developed AIDS in 1987 and began treatment with zidovudine in 1989. One year later he developed left apical pleural blebs, a pneumothorax and an exudative pleural effusion. A malignant mesothelioma developed at the pleural blebs in the left apex. He was treated with adriamycin but rapid progression of the malignancy occurred and he died three months later. At autopsy, a malignant mesothelioma, causing respiratory failure and death, was found. The patient had no exposure to asbestos and asbestosis was not present at autopsy. We postulate that the development of malignant mesothelioma was probably related to HIV immune suppression or HIV and/or cytomegalovirus or zidovudine and is a complication of AIDS similar to the development of other malignant neoplasms in patients with AIDS.

Entities:  

Mesh:

Year:  1993        PMID: 8131480     DOI: 10.1378/chest.103.4.1268

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  4 in total

Review 1.  Mesothelioma: cases associated with non-occupational and low dose exposures.

Authors:  G Hillerdal
Journal:  Occup Environ Med       Date:  1999-08       Impact factor: 4.402

2.  Susceptibility and resistance in the genesis of asbestos-related mesothelioma.

Authors:  Claudio Bianchi; Tommaso Bianchi
Journal:  Indian J Occup Environ Med       Date:  2008-08

3.  Is there a role of immunosenescence in the pathogenesis of malignant mesothelioma? A case study.

Authors:  Abhishek Biswas
Journal:  Lung India       Date:  2016 May-Jun

Review 4.  Curcumin as an Anticancer Agent in Malignant Mesothelioma: A Review.

Authors:  Alfonso Baldi; Antonio De Luca; Patrizia Maiorano; Costantino D'Angelo; Antonio Giordano
Journal:  Int J Mol Sci       Date:  2020-03-07       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.